Base de dados : MEDLINE
Pesquisa : C04.588.274.120.250 [Categoria DeCS]
Referências encontradas : 12135 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1214 ir para página                         

  1 / 12135 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453918
[Au] Autor:Vannas MJ; Boyd S; Färkkilä MA; Arola J; Isoniemi H
[Ad] Endereço:Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki, Finland.
[Ti] Título:Value of brush cytology for optimal timing of liver transplantation in primary sclerosing cholangitis.
[So] Source:Liver Int;37(5):735-742, 2017 May.
[Is] ISSN:1478-3231
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIMS: Primary sclerosing cholangitis is associated with a high risk of cholangiocarcinoma. Here, we investigated the value of surveillance for dysplasia using brush cytology, to determine the optimal timing of liver transplantation in primary sclerosing cholangitis. We compared our preoperative findings, with the final explanted liver histopathology. METHODS: 126 consecutive patients were transplanted for primary sclerosing cholangitis from 1984 to 2012. Patients were divided into two groups: symptomatic (n=91), and asymptomatic (n=35). RESULTS: Brush cytology was available for 101 patients; 66 symptomatic and 35 asymptomatic. Suspicious cytological findings were found in nine patients (14%) in the symptomatic group and 17 (49%) in the asymptomatic group. DNA flow cytometry was available for 49 patients (25 symptomatic, 24 asymptomatic), with aneuploidy detected in six patients (24%) in the symptomatic group and 15 (63%) in the asymptomatic group. Explanted liver histology showed biliary dysplasia or cholangiocarcinoma in 11 symptomatic patients (12%) and 15 asymptomatic patients (43%). A combination of cytological and DNA flow cytometry findings resulted in a test sensitivity of 68%, with a specificity of 86%. Ten-year survival in the asymptomatic group was 91%. CONCLUSIONS: Dysplasia surveillance using brush specimens may help to select those patients likely to benefit from early liver transplantation. It remains unclear as to whether surveillance with brush cytology improves long-term survival, but there is presently no better method with which to predict transplantation timing.
[Mh] Termos MeSH primário: Sistema Biliar/patologia
Colangite Esclerosante/patologia
Colangite Esclerosante/cirurgia
Citodiagnóstico/métodos
Células Epiteliais/patologia
Transplante de Fígado
[Mh] Termos MeSH secundário: Adulto
Neoplasias dos Ductos Biliares/patologia
Carcinoma Hepatocelular/patologia
Colangiocarcinoma/patologia
Colangiopancreatografia Retrógrada Endoscópica
Diagnóstico Diferencial
Feminino
Finlândia
Seres Humanos
Estimativa de Kaplan-Meier
Neoplasias Hepáticas/patologia
Masculino
Meia-Idade
Sistema de Registros
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1111/liv.13276


  2 / 12135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29480952
[Au] Autor:Loveday BPT; Knox JJ; Dawson LA; Metser U; Brade A; Horgan AM; Gallinger S; Greig PD; Moulton CA
[Ad] Endereço:Department of Surgery, Toronto General Hospital, Ontario, Canada.
[Ti] Título:Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada.
[So] Source:J Surg Oncol;117(2):213-219, 2018 Feb.
[Is] ISSN:1096-9098
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVES: Neoadjuvant chemoradiation and liver transplantation may be offered for unresectable perihilar cholangiocarcinoma (pCCA). This study aimed to determine the dropout rate and survival of patients who entered a national tri-modality protocol. METHOD: Patients enrolled Jan 2009-Aug 2015 were included. Enrolment criteria: ≤65 years, brush biopsy-proven unresectable pCCA <3.5 cm diameter. Conformal radiotherapy was given concurrently with Capecitabine. Following surgical staging, patients received maintenance Cisplatin and Gemcitabine until transplant or progression. Time to event analyses were performed from start of neoadjuvant therapy. RESULTS: Of 43 patients screened, 18 started treatment; median age 53.9 (26.7-62.8) years, tumour diameter 2.7 (2.0-3.4) cm. 11/18 dropped out due to metastatic disease identified during chemoradiation (n = 2), surgical staging (n = 6), or maintenance chemotherapy (n = 3). Six patients underwent transplantation. Median follow up was 17.6 (4.9-57.7) months and overall survival 16.4 months. One and two year survival was 70.6% and 35.3%, respectively. One and 2 year post transplant survival was 83.3% and 55.6%. Median progression free survival was 11.5 months. CONCLUSION: Neoadjuvant chemoradiation and liver transplantation for unresectable early stage pCCA is feasible, although with high rates of dropout and disease progression. Further research is required to determine factors to help select patients for treatment.
[Mh] Termos MeSH primário: Neoplasias dos Ductos Biliares/terapia
Quimiorradioterapia
Tumor de Klatskin/terapia
Transplante de Fígado
Terapia Neoadjuvante
[Mh] Termos MeSH secundário: Adulto
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias dos Ductos Biliares/patologia
Cisplatino/administração & dosagem
Terapia Combinada
Desoxicitidina/administração & dosagem
Desoxicitidina/análogos & derivados
Feminino
Seguimentos
Seres Humanos
Tumor de Klatskin/patologia
Masculino
Meia-Idade
Prognóstico
Estudos Prospectivos
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0W860991D6 (Deoxycytidine); B76N6SBZ8R (gemcitabine); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180227
[St] Status:MEDLINE
[do] DOI:10.1002/jso.24833


  3 / 12135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465585
[Au] Autor:Zhang C; Zhou J; Kou K; Liu S; We F; Wang G
[Ad] Endereço:First Hospital of Jilin University, Changchun, Jilin, China.
[Ti] Título:Occurrence of signet-ring cell carcinoma with cholangiocarcinoma 25 years after choledochal cyst excision: A case report.
[So] Source:Medicine (Baltimore);97(8):e9956, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Choledochal cysts are a risk factor for the development of cholangiocarcinoma. Hence, complete surgical excision is the preferred treatment in most cases. However, cholangiocarcinoma still can develop from the remnant biliary system after surgical excision. Signet-ring cell carcinoma is a rare type of cancer of the biliary system, and the occurrence of signet-ring cell carcinoma after surgical excision of choledochal cysts has not been reported in the English literature to date. PATIENT CONCERNS: We report a case of a 32-year-old woman who presented with a 1-month history of abdominal pain,obstructive jaundice, itching, and fever. The patient had undergone choledochal cyst excision and Roux-en-Y hepatico-jejunostomy 25 years previously and had now developed signet-ring cell carcinoma along with cholangiocarcinoma at the anastomotic site. DIAGNOSES:: signet-ring cell carcinoma along with cholangiocarcinoma. INTERVENTIONS: Interventions included laparotomy with evacuation,blood transfusion,and other adjuvant therapy. OUTCOMES: The patient died five months later. LESSONS: Surgery is the best treatment for CCCs, and the surgeon should try to remove as much as of the bile duct cyst as possible.
[Mh] Termos MeSH primário: Neoplasias dos Ductos Biliares/etiologia
Procedimentos Cirúrgicos do Sistema Biliar/efeitos adversos
Carcinoma de Células em Anel de Sinete/etiologia
Colangiocarcinoma/etiologia
Cisto do Colédoco/cirurgia
Complicações Pós-Operatórias/etiologia
[Mh] Termos MeSH secundário: Adulto
Anastomose em-Y de Roux/efeitos adversos
Feminino
Seres Humanos
Jejuno/cirurgia
Fígado/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009956


  4 / 12135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390348
[Au] Autor:Eso Y; Uza N; Yamagishi H; Imada K; Kimura Y; Masui T; Kodama Y; Seno H
[Ad] Endereço:Department of Gastroenterology and Hepatology.
[Ti] Título:Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report.
[So] Source:Medicine (Baltimore);96(50):e9217, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: It is often challenging to discriminate between intrahepatic cholangiocarcinoma (ICC) and metastatic liver tumors, especially when the hepatic tumor is small and of a mass-forming type. PATIENT CONCERNS: We report a 69-year-old woman presented at our hospital with a small solid tumor in the head of the pancreas that was previously discovered during a medical checkup. DIAGNOSES: The patient was diagnosed with synchronous pancreatic cancer and ICC. INTERVENTIONS: The patient underwent clinical, histological, immunohistological, and KRAS mutational analysis. OUTCOMES: Computed tomography revealed poorly enhanced small nodules in both the pancreatic head and liver. Biopsies of both nodules revealed adenocarcinoma; however, it was unclear whether the hepatic lesion was a metastasis of the pancreatic tumor or primary ICC. KRAS mutational analysis from FFPE biopsy samples revealed a discordance of mutation status between the tumors. Therefore, the patient was diagnosed with synchronous pancreatic cancer and ICC, whereupon she underwent hepatopancreatoduodenectomy. LESSONS: KRAS mutational analysis of FFPE biopsy samples can be utilized for differentiating between ICC and metastatic liver tumor.
[Mh] Termos MeSH primário: Neoplasias dos Ductos Biliares/diagnóstico
Neoplasias dos Ductos Biliares/genética
Colangiocarcinoma/diagnóstico
Colangiocarcinoma/genética
Neoplasias Primárias Múltiplas/diagnóstico
Neoplasias Primárias Múltiplas/genética
Neoplasias Pancreáticas/diagnóstico
Neoplasias Pancreáticas/genética
Proteínas Proto-Oncogênicas p21(ras)/genética
[Mh] Termos MeSH secundário: Idoso
Neoplasias dos Ductos Biliares/cirurgia
Colangiocarcinoma/cirurgia
Análise Mutacional de DNA
Diagnóstico Diferencial
Feminino
Seres Humanos
Neoplasias Primárias Múltiplas/cirurgia
Neoplasias Pancreáticas/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (KRAS protein, human); EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009217


  5 / 12135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465572
[Au] Autor:Liu J; Xue P; Deng J
[Ad] Endereço:Department of General Surgery, Guangzhou Panyu Central Hospital.
[Ti] Título:Therapeutic effect of photodynamic therapy for nonresectable cholangiocarcinoma: Protocol for a meta-analysis and systematic review.
[So] Source:Medicine (Baltimore);97(8):e9863, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cholangiocarcinoma is a malignant neoplasia that originates in the bile ducts. Most patients with cholangiocarcinoma are inoperable at the time of diagnosis. photodynamic therapy (PDT) is a fairly well accepted treatment in clinical practice for nonresectable cholangiocarcinoma (NCC) but lack of quantitatively assessment. Herein, we present a protocol for a systematic review to identify the efficacy of PDT in patients with NCC. METHODS: We will search PUBMED, SpringerLink, Cochrane Library, the Chinese Biomedical database (CBM), WanFang data, China National Knowledge Infrastructure (CNKI) up to December 2017. Studies will be screened by title, abstract, and full text independently and in duplicate. Studies that report PDT in patients with nonresectable cholangiocarcinoma will be eligible for inclusion. Outcome variables will be assessed included survival benefit, health status and quality of life, and adverse events with photodynamic therapy. Assessment of risk of bias and data synthesis will be performed using Revman software. The hazard ratios will be extracted from the survival curves using Tierney Method. Heterogeneity among studies will be assessed using the I statistic. RESULTS: This study will review randomized controlled trials, cohort studies, or retrospective studies and quantitatively assess the efficacy of PDT in patients with NCC for the latest evidence-based recommendation. CONCLUSION: This study will evaluate therapeutic effect of PDT in patients with NCC systematically. We expect that the results from this systematic review for clinical trials will help inform clinical practice in NCC.
[Mh] Termos MeSH primário: Neoplasias dos Ductos Biliares/tratamento farmacológico
Colangiocarcinoma/tratamento farmacológico
Fotoquimioterapia
[Mh] Termos MeSH secundário: Protocolos Clínicos
Seres Humanos
Avaliação de Resultados (Cuidados de Saúde)
Fotoquimioterapia/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009863


  6 / 12135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29352306
[Au] Autor:Peraldo-Neia C; Cavalloni G; Fenocchio E; Cagnazzo C; Gammaitoni L; Cereda S; Nasti G; Satolli MA; Aprile G; Reni M; Avallone A; Spadi R; Venesio T; Martin V; Doglioni C; Frattini M; Aglietta M; Leone F
[Ad] Endereço:Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO), IRCCS-Institute of Candiolo, Candiolo, Italy.
[Ti] Título:Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.
[So] Source:PLoS One;13(1):e0191593, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The association of anti-EGFR to gemcitabine and oxaliplatin (GEMOX) chemotherapy did not improve survival in biliary tract carcinoma (BTC) patients. Multiple mechanisms might be involved in the resistance to anti-EGFR. Here, we explored the mutation profile of EGFR extracellular domain (ECD), of tyrosine kinase domain (TKD), and its amplification status. EGFR mutational status of exons 12, 18-21 was analyzed in 57 tumors by Sanger sequencing. EGFR amplification was evaluated in 37 tumors by Fluorescent In Situ Hybridization (FISH). Kaplan-Meier curves were calculated using the log-rank test. Six patients had mutations in exon 12 of EGFR ECD and 7 in EGFR TKD. Neither EGFR ECD nor TKD mutations affected progression free survival (PFS) or overall survival (OS) in the entire population. In the panitumumab plus GEMOX (P-GEMOX) arm, ECD mutated patients had a worse OS, while EGFR TKD mutated patients had a trend towards shorter PFS and OS. Overall, the presence of mutations in EGFR or in its transducers did not affect PFS or OS, while the extrahepatic cholangiocarcinoma (ECC) mutated patients had a worse prognosis compared to WT. Nineteen out of 37 tumors were EGFR amplified, but the amplification did not correlate with survival. ECC EGFR amplified patients had improved OS, whereas the amplification significantly correlated with poor PFS (p = 0.03) in gallbladder carcinoma patients. The high molecular heterogeneity is a predominant feature of BTC: the alterations found in this work seem to have a prognostic impact rather than a predictive role towards anti-EGFR therapy.
[Mh] Termos MeSH primário: Neoplasias do Sistema Biliar/tratamento farmacológico
Neoplasias do Sistema Biliar/genética
Genes erbB-1
Mutação
Receptor do Fator de Crescimento Epidérmico/genética
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/administração & dosagem
Anticorpos Monoclonais/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias dos Ductos Biliares/tratamento farmacológico
Neoplasias dos Ductos Biliares/genética
Neoplasias dos Ductos Biliares/metabolismo
Neoplasias do Sistema Biliar/metabolismo
Colangiocarcinoma/tratamento farmacológico
Colangiocarcinoma/genética
Colangiocarcinoma/metabolismo
Análise Mutacional de DNA
Desoxicitidina/administração & dosagem
Desoxicitidina/análogos & derivados
Desoxicitidina/uso terapêutico
Neoplasias da Vesícula Biliar/tratamento farmacológico
Neoplasias da Vesícula Biliar/genética
Neoplasias da Vesícula Biliar/metabolismo
Amplificação de Genes
Seres Humanos
Hibridização in Situ Fluorescente
Estimativa de Kaplan-Meier
Compostos Organoplatínicos/administração & dosagem
Compostos Organoplatínicos/uso terapêutico
Prognóstico
Receptor do Fator de Crescimento Epidérmico/antagonistas & inibidores
Receptor do Fator de Crescimento Epidérmico/metabolismo
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Organoplatinum Compounds); 04ZR38536J (oxaliplatin); 0W860991D6 (Deoxycytidine); 6A901E312A (panitumumab); B76N6SBZ8R (gemcitabine); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180121
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191593


  7 / 12135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29337065
[Au] Autor:Xu Y; Yao Y; Zhong X; Leng K; Qin W; Qu L; Cui Y; Jiang X
[Ad] Endereço:Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150086, China; The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry of Education, Harbin, Heilongjiang Province, 150086, China.
[Ti] Título:Downregulated circular RNA hsa_circ_0001649 regulates proliferation, migration and invasion in cholangiocarcinoma cells.
[So] Source:Biochem Biophys Res Commun;496(2):455-461, 2018 02 05.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cholangiocarcinoma (CCA) is one of the most aggressive malignancies with increasing worldwide incidence and is characterized by unfavorable prognosis due to its early invasive characteristics and poor response to chemotherapy or radiotherapy. Accumulating evidence has indicated that aberrantly expressed circular RNAs (circRNAs) are involved in cancer development and progression. However, their clinical values and biological roles in CCA remain unclear. Hsa_circ_0001649, a novel cancer-related circRNA, has been previously reported to be downregulated in hepatocellular carcinoma and gastric cancer. In the present study, qRT-PCR was carried out to measure the expression of hsa_circ_0001649 in CCA tissue samples and cell lines, and the correlation between hsa_circ_0001649 expression and clinicopathologic features was analyzed. The biological functions of hsa_circ_0001649 in CCA cells were evaluated both in vitro and in vivo. As a result, hsa_circ_0001649 was aberrantly downregulated in CCA tissues and cells, and this downregulation was associated with tumor size and differentiation grade in CCA. In addition, hsa_circ_0001649 overexpression caused tumor suppressive effects via inhibiting cell proliferation, migration and invasion; inducing cell apoptosis in KMBC and Huh-28 cells. On the contrary, silencing of hsa_circ_0001649 caused the opposite phenotypes. Furthermore, tumor xenograft study confirmed the in vitro results. Collectively, our findings suggest that hsa_circ_0001649 might be a rational CCA-related therapeutic target.
[Mh] Termos MeSH primário: Neoplasias dos Ductos Biliares/genética
Ductos Biliares Intra-Hepáticos/metabolismo
Colangiocarcinoma/genética
Regulação Neoplásica da Expressão Gênica
RNA/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Animais
Neoplasias dos Ductos Biliares/metabolismo
Neoplasias dos Ductos Biliares/patologia
Neoplasias dos Ductos Biliares/cirurgia
Ductos Biliares Intra-Hepáticos/patologia
Ductos Biliares Intra-Hepáticos/cirurgia
Linhagem Celular Tumoral
Movimento Celular
Proliferação Celular
Colangiocarcinoma/metabolismo
Colangiocarcinoma/patologia
Colangiocarcinoma/cirurgia
Regulação para Baixo
Feminino
Seres Humanos
Masculino
Camundongos Endogâmicos C57BL
Camundongos Nus
Meia-Idade
Gradação de Tumores
Invasividade Neoplásica
Estadiamento de Neoplasias
Transplante de Neoplasias
RNA/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (RNA, circular); 63231-63-0 (RNA)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE


  8 / 12135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374731
[Au] Autor:Saito N; Shirai Y; Horiuchi T; Sugano H; Shiba H; Sakamoto T; Uwagawa T; Yanaga K
[Ad] Endereço:Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan h24dr-saito@jikei.ac.jp.
[Ti] Título:Preoperative Platelet to Albumin Ratio Predicts Outcome of Patients with Cholangiocarcinoma.
[So] Source:Anticancer Res;38(2):987-992, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The purpose of this study was to evaluate the prognostic index of the preoperative platelet to albumin ratio (PAR) in patients who underwent primary resection for cholangiocarcinoma. PATIENTS AND METHODS: A total of 59 patients were divided into two groups: those with PAR ≥72.6×10 or <72.6×10 according to the area under the receiver operating characteristics curve. RESULTS: PAR was significantly inversely associated with overall (OS) and disease-free (DFS) survival on univariate analysis. PAR showed significance on multivariate analysis for OS (hazard ratio=6.232, 95% confidence interval=1.283-30.279, p=0.023), along with tumor differentiation (p=0.009), nodal involvement (p=0.001), intraoperative blood loss (p=0.001), and serum carcinoembryonic antigen (CEA) (p=0.012). High PAR was also significantly associated poor DFS on multivariate analysis (hazard ratio(HR)=4.422, 95% confidence interval(CI)=1.168-16.732, p=0.029), along with tumor differentiation (p=0.009). CONCLUSION: PAR is a useful prognostic index for OS and DFS in patients with cholangiocarcinoma after primary resection. By accumulating cases prospectively, this new index may be a reference for use before neoadjuvant chemotherapy.
[Mh] Termos MeSH primário: Albuminas/metabolismo
Neoplasias dos Ductos Biliares/patologia
Ductos Biliares Intra-Hepáticos/patologia
Plaquetas/patologia
Colangiocarcinoma/patologia
Hepatectomia/mortalidade
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias dos Ductos Biliares/metabolismo
Neoplasias dos Ductos Biliares/cirurgia
Ductos Biliares Intra-Hepáticos/metabolismo
Ductos Biliares Intra-Hepáticos/cirurgia
Biomarcadores Tumorais/análise
Colangiocarcinoma/metabolismo
Colangiocarcinoma/cirurgia
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Cuidados Pré-Operatórios
Prognóstico
Estudos Retrospectivos
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Albumins); 0 (Biomarkers, Tumor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  9 / 12135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29317591
[Au] Autor:Tasch JJ; Dube N
[Ad] Endereço:Graduate Medical Education, Camden Clark Medical Center, Parkersburg, WV, USA.
[Ti] Título:An Unusual Presentation of Advanced Intrahepatic Cholangiocarcinoma: When Biopsy Results Fail.
[So] Source:Am J Case Rep;19:35-40, 2018 Jan 10.
[Is] ISSN:1941-5923
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND Intrahepatic cholangiocarcinoma is a rare condition which typically occurs in males between 50 and 70 years of age, and presents with symptoms related to biliary obstruction including jaundice, pruritus, and dark urine. Other common symptoms at presentation include abdominal pain, weight loss, and fever. CASE REPORT We present a case of a 67-year-old female initially presenting with chest pain at rest, found to have a lung nodule on diagnostic imaging at the time of admission. On further imaging, a 9 cm liver lesion was incidentally discovered, initially suspicious for hepatocellular carcinoma on imaging, with initial biopsy staining CK7 positive, and CK20 negative. The patient also had an elevated alpha-fetoprotein level. Biopsy results were later confirmed as moderately differentiated adenocarcinoma consistent with intrahepatic cholangiocarcinoma. CONCLUSIONS This report illustrates an unusual presentation of intrahepatic cholangiocarcinoma. Although rare, cholangiocarcinoma is diagnosed most frequently as an incidental finding on imaging studies. With quick work-up and successful biopsy results, patients can undergo surgical or chemo-radiation therapy earlier, potentially leading to a longer survival time.
[Mh] Termos MeSH primário: Neoplasias dos Ductos Biliares/diagnóstico
Biomarcadores Tumorais/sangue
Colangiocarcinoma/diagnóstico
alfa-Fetoproteínas/metabolismo
[Mh] Termos MeSH secundário: Idoso
Neoplasias dos Ductos Biliares/sangue
Ductos Biliares Intra-Hepáticos/patologia
Biópsia
Colangiocarcinoma/sangue
Diagnóstico Diferencial
Feminino
Seres Humanos
Achados Incidentais
Estadiamento de Neoplasias
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (alpha-Fetoproteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE


  10 / 12135 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29275776
[Au] Autor:Al-Zahir MZ; AlAmeel T
[Ad] Endereço:Department of Medicine, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia.
[Ti] Título:Extrahepatic cholangiocarcinoma with prolonged survival: a case report.
[So] Source:J Med Case Rep;11(1):357, 2017 Dec 25.
[Is] ISSN:1752-1947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cholangiocarcinoma has poor prognosis and short term-survival. Here, we report the case of a patient with unusually prolonged survival. CASE PRESENTATION: Our patient was a 56-year-old Arab man with a 6-month history of obstructive jaundice. A computed tomography scan of his abdomen revealed a mass at the confluence of the hepatic ducts with suspected malignant strictures on endoscopy. A positive tissue diagnosis was achieved more than 18 months after commencement of his symptoms. He remained functional throughout this period despite recurrent episodes of cholangitis. CONCLUSIONS: Cholangiocarcinoma is a presumably fatal disease, especially because patients tend to present late with unresectable disease. Many patient-related and disease-related factors may alter survival.
[Mh] Termos MeSH primário: Neoplasias dos Ductos Biliares/diagnóstico por imagem
Ductos Biliares Extra-Hepáticos/diagnóstico por imagem
Tumor de Klatskin/diagnóstico por imagem
[Mh] Termos MeSH secundário: Neoplasias dos Ductos Biliares/complicações
Neoplasias dos Ductos Biliares/patologia
Ductos Biliares Extra-Hepáticos/patologia
Colangiocarcinoma/complicações
Colangiocarcinoma/diagnóstico por imagem
Colangiocarcinoma/patologia
Colangiopancreatografia Retrógrada Endoscópica
Colangite/etiologia
Seres Humanos
Icterícia Obstrutiva/etiologia
Tumor de Klatskin/complicações
Tumor de Klatskin/patologia
Masculino
Meia-Idade
Taxa de Sobrevida
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180130
[Lr] Data última revisão:
180130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171226
[St] Status:MEDLINE
[do] DOI:10.1186/s13256-017-1519-5



página 1 de 1214 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde